🇪🇺 Seebri® Breezhaler® in European Union

EMA authorised Seebri® Breezhaler® on 28 September 2012

Marketing authorisation

EMA — authorised 28 September 2012

  • Application: EMEA/H/C/002430
  • Marketing authorisation holder: Novartis Europharm Limited
  • Local brand name: Seebri Breezhaler
  • Indication: Seebri Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
  • Status: approved

Read official source →

Frequently asked questions

Is Seebri® Breezhaler® approved in European Union?

Yes. EMA authorised it on 28 September 2012.

Who is the marketing authorisation holder for Seebri® Breezhaler® in European Union?

Novartis Europharm Limited holds the EU marketing authorisation.